Find → Understand → Decide
Emi-Le
Discovery priority: LOW · UNKNOWN
Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.
Why investigate?
Why stranded (event context): inadequate public evidence
Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established
Company/trial failed before biology? UNKNOWN
Biology implicated: UNCLEAR · Failure context: UNKNOWN
MODEL INFERENCE · UNKNOWN confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.
Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN
Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.
Existing buyer gates
Human Signal: UNKNOWN
Cheap Truth: UNKNOWN
Clean Rights: UNKNOWN
Market Pull: UNKNOWN
No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.
Evidence timeline
2025-06-30 · program:continuing clinical development despite corporate restructuring
Reporting period end, not proof of continued development today
SOURCE TEXT · Exact source
As part of the strategic restructuring and reprioritization plan, the Company also announced that it would reduce its research activities, eliminate its internal pipeline development efforts and, in the near term, focus Emi-Le development efforts on breast cancer to enable the generation of additional safety, tolerability and clinical activity data while continuing to support the dose escalation portion of the Company’s Phase 1 clinical trial of XMT-2056 and its ongoing collaborations.
Present scoped control, intervening transfers, obligations and availability unverified
Interpretation: inadequate public evidence · MACHINE_REVIEW · LOW
Provenance and retrieval scope
{
"hash": "461124a4dbc9080b07af422c9915e054bde2581120cd231f9df220e69212e2ab",
"metadata": {
"complete": true,
"content_hash": "461124a4dbc9080b07af422c9915e054bde2581120cd231f9df220e69212e2ab",
"failed": false,
"last_checked": 1790027032.7475095,
"last_success": 1790027032.7475095,
"live_verified": true,
"scope": "Historical filing text; present ownership/availability not confirmed"
},
"raw_path": "research/obz7_sources/461124a4dbc9080b07af422c9915e054bde2581120cd231f9df220e69212e2ab.html",
"type": "sec",
"url": "https://www.sec.gov/Archives/edgar/data/1442836/000162828025040017/mrsn-20250630.htm"
}2025-09-30 · program:continuing clinical development despite corporate restructuring
Reporting period end, not proof of continued development today
SOURCE TEXT · Exact source
As part of the strategic restructuring and reprioritization plan, the Company also announced that it would reduce its research activities, eliminate its internal pipeline development efforts and, in the near term, focus Emi-Le development efforts on breast cancer to enable the generation of additional safety, tolerability and clinical activity data while continuing to support the dose escalation portion of the Company’s Phase 1 clinical trial of XMT-2056 and its ongoing collaborations.
Present scoped control, intervening transfers, obligations and availability unverified
Interpretation: inadequate public evidence · MACHINE_REVIEW · LOW
Provenance and retrieval scope
{
"hash": "814c5248219607362ac309a1fdfb254f6b0d413a86707d1dfbaf7c818007ff09",
"metadata": {
"complete": true,
"content_hash": "814c5248219607362ac309a1fdfb254f6b0d413a86707d1dfbaf7c818007ff09",
"failed": false,
"last_checked": 1790027033.7340825,
"last_success": 1790027033.7340825,
"live_verified": true,
"scope": "Historical filing text; present ownership/availability not confirmed"
},
"raw_path": "research/obz7_sources/814c5248219607362ac309a1fdfb254f6b0d413a86707d1dfbaf7c818007ff09.html",
"type": "sec",
"url": "https://www.sec.gov/Archives/edgar/data/1442836/000162828025052202/mrsn-20250930.htm"
}Freshness is claim-specific
Fetching an old filing today does not establish current ownership or program status.
clinicaltrials · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
sec · STALE · Historical filing text; present ownership/availability not confirmed · checked 2026-09-21T21:43:52.747509+00:00
sec · STALE · Historical filing text; present ownership/availability not confirmed · checked 2026-09-21T21:43:53.734082+00:00
Registry observations (0)